Articles

CHICAGO—A human monoclonal antibody that blocks a receptor that down regulates T-cell responses improves long-term survival in patients with previously treated advanced melanoma, according to the results of a phase 3 trial.

SAN DIEGO—A program that calls for direct communication between interdisciplinary caregivers may help decrease falls in a hematology/oncology inpatient unit, according to data reported by Boston researchers.

Deborah O’Connor, RN, MS, CNML, at the Brigham and Women’s Hospital in Boston, and her colleagues presented the results of a falls prevention program that was “piloted” in a hematopoietic stem cell transplant (HSCT) unit at a tertiary academic teaching hospital.

Bevacizumab (Avastin, Genentech) has been a popular first-line treatment for metastatic breast cancer since 2008, when the US Food and Drug Administration (FDA) granted special, fast-track approval for use in combination with paclitaxel. The accelerated approval was based on positive early findings from the E2100 trial, which showed that the addition of bevacizumab added 5.5 months of progression-free survival (PFS) over paclitaxel alone. Read More ›

A healthy work environment is one in which people are valued and priority is given to the multiple aspects of the workplace that affect employees’ ability to function well in order to accomplish the goals of the organization.¹ Since its early days, nursing has been a profession of service in a high-stress, ever-changing healthcare environment, often without appropriate thanks, reward, recognition, or appreciation. The psychological implication Read More ›

This past April, Albert Einstein Cancer Center was selected to join the National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP), which, in the words of William J. Tester, MD, FACP, medical director of Einstein’s Cancer Center, offers “an opportunity to bring more resources to our patients.”